Novacyt S.A. Publication of Annual Report and Notice of AGM (0449A)
24 Mayo 2019 - 1:00AM
UK Regulatory
TIDMNCYT
RNS Number : 0449A
Novacyt S.A.
24 May 2019
Publication of Annual Report and Notice of AGM
Paris, France and Camberley, UK - 24 May 2019 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, today announces that the Company's Annual
Report and Accounts ("Annual Report") for the year ended 31
December 2018 has been published and uploaded to the Company's
website. The Annual Report will also be posted in hard copy to all
shareholders that hold ordinary shares through CREST Depository
Interests (CDIs). The Notice of the Annual General Meeting (AGM)
and a Form of Proxy have been posted to shareholders.
Electronic copies of these documents are available on the
Company's website at www.novacyt.com. Alternatively, a hardcopy is
available from either 13 Avenue Morane Saulnier, 78140
Vélizy-Villacoublay, France or Unit 1, Watchmoor Point, Watchmoor
Road, Camberley, Surrey, GU15 3AD or will be posted upon request
from investor.relations@novacyt.com.
The AGM will be held on 19 June, at 2.00 p.m. (Paris time)
Cabinet Racine, Paris, 40 rue de Courcelles, 75008, Paris,
France.
- End -
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and Joint
Broker)
Matthew Johnson / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
WG Partners (Joint Broker)
Nigel Birks / Chris Lee / Claes Spång
+44 (0)203 705 9330
FTI Consulting (International)
Brett Pollard / Victoria Foster Mitchell
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com /
victoria.fostermitchell@fticonsulting.com
Mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com /
astrid.villette@fticonsulting.com
About Novacyt Group
The Novacyt Group is a rapidly growing, international
diagnostics business generating an increasing portfolio of in vitro
and molecular diagnostic tests. Its core strengths lie in
diagnostics product development, commercialisation, contract design
and manufacturing. The Company's lead business units comprise of
Primerdesign and Lab21 Products, supplying an extensive range of
high quality assays and reagents worldwide. The Group directly
serves oncology, microbiology, haematology and serology markets as
do its global partners, which include major corporates.
For more information please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOAPGUBGAUPBGAW
(END) Dow Jones Newswires
May 24, 2019 02:00 ET (06:00 GMT)
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024